

The University of Manchester Faculty of Biology, Medicine and Health

*Professor Nigel Hooper
Vice Dean for Research and Innovation*



Our research vision

to undertake world-class discovery science, develop effective clinical translation, and facilitate implementation of advances in healthcare for the benefit of society in Manchester, the UK and across the globe



Our strategic research domains

- Drive large-scale interdisciplinary research projects and collaborative working
- Support staff to deliver innovative, world-leading research
- Aligned closely to the strategic priorities of our partners
- Exploit opportunities presented by £6 billion devolved health and social care budget (DevoManc)



Cancer

- Cancer Research UK (CRUK) Major Centre
- Christie Hospital
- Manchester Cancer Research Centre (MCRC)
- CRUK Lung Cancer Centre of Excellence
- Movember Centre of Excellence in Prostate Cancer




CANCER
RESEARCH
UK

MANCHESTER
INSTITUTE

Biomedical Research Centre

- Cancer prevention & early detection
- Advanced radiotherapy (incl. proton beam therapy)
- Cancer precision medicine

- Lung
- Melanoma
- Prostate
- Ovarian
- Breast
- Haematological



Opportunities

- Cancer immunology
- Living longer with cancer

Cardiovascular, Endocrine & Metabolic Sciences

Cardiovascular medicine and science

- Hypertension
- Cardiac physiology
- Human genetics of cardiovascular disease

Endocrinology and metabolism

- Metabolic and endocrine disease
- Gut-brain interactions
- Genetic circuits involved in development

Opportunity
- Biological clocks





Cellular & Developmental Systems

Wellcome Centre for Cell-Matrix Research

- Immuno matrix
 - Mechano matrix
 - Chrono matrix
- Biological timing
 - Cell matrix biology
 - Development & disease
 - Gene expression, chromatin & signalling
 - Cell dynamics
 - Regenerative medicine

Opportunities

- Quantitative & dynamic biology
- Biological clocks



Evolution, Systems & Genomics

Manchester Centre for Genomic Medicine – 100,000 genomes project

- Antimicrobial resistance
- Bioinformatics
- Evolutionary biology
- Metagenomes
- Modelling
- Molecular epidemiology
- Organismal behaviour
- Protein structure evolution



Opportunity

- Computational biology

Infection, Immunity, Inflammation & Repair

- Manchester Collaborative Centre for Inflammation Research (MCCIR)
- Manchester Fungal Infection Group: global leaders on aspergillosis
- Arthritis Research UK centres: Genetics & Genomics, Epidemiology

Biomedical Research Centre

- Dermatology
- Musculoskeletal
- Respiratory medicine



- Chronic inflammatory diseases: musculoskeletal, dermatology, respiratory
- Explorative immunology across the life course
- Regenerative medicine, incl. matrix biology
- Infection: mycology, bacteriology & parasite immunology

Opportunities

- Precision medicine for immune-mediated inflammatory diseases
- Cancer immunology
- Chronic wounds

Neuroscience & Mental Health

ESRC International Centre for Language and Communication Development

Biomedical Research Centre

- Hearing health
- Cognitive neuroscience
- Language
- Communication & hearing
- Mental health
- Neurodegeneration
- Stroke
- Systems & computational neuroscience
- Vision research

Opportunities

- Neuro oncology
- Neurovascular diseases



Population Health

Digital health

- Health e-Research Centre (HeRC)



Health
e-Research
Centre

Applied Health Research

- NIHR Patient Safety Centre
- NIHR Clinical Research Facility
- Clinical Trials Unit
- NIHR Collaboration for Leadership in Applied Health Research (CLARHC)



Evidence synthesis Clinical trials

Biostatistics

Informatics

Health economics

Behavioural & social sciences

Patient & public involvement & engagement

Opportunities

- Minimising health inequalities (North-South divide)
- Centre for a sustainable NHS
- Learning health systems


Platform Sciences & Technology - cross-cutting approaches

- **Advanced materials** – use of advanced materials (incl. graphene) and engineering, cell based therapies
- **Integrated imaging** – translational pipeline for identification and characterisation of new imaging biomarkers
- **Precision medicine** – integration of health- & bio-informatics, systems medicine, biostatistics - translate clinical genomic & proteomic data into platforms for personalised diagnosis – bridge the gap from biomarker studies to implementation

- National Graphene Institute
- Graphene Engineering Innovation Centre
- Sir Henry Royce Institute for Advanced Materials



Combining technology and innovation to address major health challenges



Greater Manchester: A regional innovation ecosystem

Proximity to
Manchester's
"sick" population

Manchester has the
lowest likelihood of a
man in England & Wales
surviving to 75 years

Devolved £6bn Health
and Social Care budget
for a population of 3.5
million

**Population
Benefit**

**Wider
Economic Gain**

**Greater Manchester
Devolution**

Health Innovation
Manchester

Manchester
Academic Health
Science Centre

**Manchester
BRC**

At the core of a regional
innovation ecosystem:

- Biomedical Research Centre
- Cancer Research UK major centre
- National Graphene Institute
- Graphene Engineering Innovation Centre
- Sir Henry Royce Institute
- Manchester Science Partnerships
- Medicines Discovery

Goal 3: Maximising the translation and impact of our research



Translational research:

- activity originating from discoveries in fundamental science (including population health, methodological research, epidemiology, applied health research, etc)
- then moving through a pipeline that encompasses hypothesis testing and elucidation of disease mechanisms, preclinical research in animal models, **through to clinical trials in humans of new drugs, devices and diagnostic procedures**
- ultimately delivery and adoption within the NHS and third sector organisations.

Goal 3: Maximising the translation and impact of our research

We will:

Maximise the potential for translation of our discovery science by adopting a more proactive approach to identifying opportunities, removing potential barriers & striving to ensure that the component parts of our translational pipeline are integrated.

Key Performance Indicators (KPIs):

- increase the amount of funding received through translation-specific funding schemes by ~30% by 2022 (from current figure of £15.3m, industry funding £17.7m)
- secure 5 MRC DPFS and 5 Wellcome Trust translational awards by 2022, and secure at least 2 EPSRC-led translational awards in the areas of advanced materials and targeted therapeutics
- identify engagement of at least 10 new researchers in translational projects by 2022 through CiC, Wellcome Trust iPTA schemes, etc